

PRESS RELEASE

ZINZINO

Corporate ID no. 556733-1045

FAO: News Editor

Gothenburg 2022-03-03

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2022

Zinzino group revenue decreased with a total of 5%, compared with the previous year.

The revenue in February for Zinzino's sales markets decreased by 4% and amounted to SEK 88.5 (92.6) million. Faun Pharma's external sales decreased by 7% and amounted to SEK 6.3 (6.8) million. Overall, the Group decreased revenues by 5% to SEK 94.8 (99.4) million compared with the previous year.

Accumulated revenue for January – February 2022 decreased by 1% to SEK 204.5 (206.4) million.

Revenues were distributed as follows:

Regions,MSEK	22-Feb	21-Feb	Change	YTD 2022	YTD 2021	Change
The Nordics	21.1	27.6	-24%	47.2	58.5	-19%
Central Europe	18.4	16.8	10%	36.9	35.2	5%
East Europe	23.3	22.5	4%	52.0	50.1	4%
South & West Europe	11.3	9.9	14%	23.7	20.0	19%
The Baltics	5.1	5.6	-9%	11.7	11.3	4%
North America	4.4	3.9	13%	8.8	7.6	16%
Asia-Pacific	4.5	6.3	-29%	10.2	11.6	-12%
Africa	0.4	0.0		0.8	0.0	
Zinzino	88.5	92.6	-4%	191.3	194.3	-2%
Faun Pharma	6.3	6.8	-7%	13.2	12.1	9%
Zinzino Group	94.8	99.4	-5%	204.5	206.4	-1%

Countries in regions:

- The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
- Central Europe: Austria, Germany, Switzerland
- East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
- South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom, Belgium, Ireland
- The Baltics: Estonia, Latvia, Lithuania
- North America: Canada, USA
- Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
- Africa: South Africa

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:

Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com

Certified Adviser: Erik Penser Bank Aktiefbolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 16:00 the 3rd of March 2022.

Zinzino is a global D2C company from Scandinavia specializing in biomarkerbased, personalized nutrition. Founded in 2005, it is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their test-based, scientifically proven nutritional supplements are available on more than 100 markets across the world. Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia, India, Taiwan and South Africa.